Document Type : Review Article

Authors

• Hany A. Zaki ¹
• Yavuz Yigit ¹
• Mohamed AM Elgassim ²
• Eman E. Shaban ³
• Stuart A Lloyd ¹
• Thamir Hashim ¹
• Mazin SE Mohamed ¹
• Aftab Mohammad Azad ⁴

¹ Hamad Medical Corporation

² Hamad General Hospital

³ Cardiology, Al Jufairi Diagnosis and Treatment, MOH, Qatar

⁴ Hamad Medical Corporation; College of Medicine - Qatar University

Abstract

Objective: The present study aimed to evaluate the clinical benefits and drawbacks of administering ECMO/
ECLS therapies to drug-intoxicated patients.
Methods: From inception until April 30, 2024, an extensive search was performed on four main databases:
PubMed, Web of Science, Cochrane Library, and EMBASE. There was no restriction on the search period. Only
the studies that reported survival to hospital discharge rates, adverse events, and the utilization of ECMO/ECLS
in the treatment of intoxicated patients were included. On the other hand, articles that did not report adverse
events or hospital discharge rates as outcomes, as well as studies published in languages other than English,
were excluded. The evaluated outcomes were the rate of survival to hospital discharge rate and the incidence
of adverse events associated with ECMO therapy. The Newcastle Ottawa scale was employed to appraise each
study to determine its methodological quality. The Comprehensive Meta-Analysis (CMA) software (version
3.0) for statistical analysis was used, with the random effects model (due to high heterogeneity among the
studies) and a 95% confidence interval.
Results: From a total search of 2216 search results, only 10 studies were included. The pooled analysis from
10 studies indicated that ECMO therapies among drug-overdosed/poisoned patients were associated with
a significant survival to hospital discharge rate of 65.6% ([95% CI: 51.5%-77.4%], p=0.030). However, the
outcomes were highly heterogeneous (I2
=83.47%), which could be attributed to the use of several medicines
by different studies. In contrast, ECMO therapies among drug-overdosed patients were associated with a
significant incidence rate of adverse events of 23.1% ([95% CI: 12.3%-39.2%], p=0.002). However, the pooled
analysis had a significant heterogeneity (I2
=70.27%).
Conclusion: Despite various health complications, extracorporeal membrane treatment enhanced survival to
hospital discharge with good neurological outcomes. Hence, it was a viable, effective, and feasible alternative
for managing drug-induced intoxication in patients.

Keywords

• Extracorporeal treatment
• ECMO therapies
• ECLS
• Drug-overdose
• Poisoning